Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 52.05
(0.97%)
EUR 52.05
(0.97%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 799.88 Million EUR | -8.97% |
| 2022 | 878.7 Million EUR | 19.93% |
| 2021 | 732.67 Million EUR | 27.55% |
| 2020 | 574.43 Million EUR | 12.37% |
| 2019 | 511.21 Million EUR | 26.95% |
| 2018 | 402.7 Million EUR | 34.96% |
| 2017 | 298.38 Million EUR | 3.66% |
| 2016 | 287.84 Million EUR | 9.1% |
| 2015 | 263.84 Million EUR | 0.97% |
| 2014 | 261.32 Million EUR | 10.76% |
| 2013 | 235.92 Million EUR | 6.1% |
| 2012 | 222.36 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 778.66 Million EUR | -2.65% |
| 2024 Q2 | 857.32 Million EUR | 10.1% |
| 2023 FY | 799.88 Million EUR | -8.97% |
| 2023 Q2 | 899.83 Million EUR | 1.65% |
| 2023 Q1 | 885.19 Million EUR | 0.74% |
| 2023 Q3 | 830.72 Million EUR | -7.68% |
| 2023 Q4 | 799.88 Million EUR | -3.71% |
| 2022 Q2 | 791.56 Million EUR | 6.27% |
| 2022 FY | 878.7 Million EUR | 19.93% |
| 2022 Q4 | 878.7 Million EUR | 13.75% |
| 2022 Q3 | 772.46 Million EUR | -2.41% |
| 2022 Q1 | 744.85 Million EUR | 1.66% |
| 2021 Q2 | 644.24 Million EUR | 8.94% |
| 2021 Q1 | 591.38 Million EUR | 2.95% |
| 2021 Q4 | 732.67 Million EUR | 6.95% |
| 2021 Q3 | 685.06 Million EUR | 6.34% |
| 2021 FY | 732.67 Million EUR | 27.55% |
| 2020 Q4 | 574.43 Million EUR | 2.27% |
| 2020 FY | 574.43 Million EUR | 12.37% |
| 2020 Q3 | 561.71 Million EUR | 3.29% |
| 2020 Q2 | 543.83 Million EUR | 3.26% |
| 2020 Q1 | 526.65 Million EUR | 3.02% |
| 2019 Q2 | 449.12 Million EUR | 5.02% |
| 2019 Q4 | 511.21 Million EUR | 13.06% |
| 2019 Q1 | 427.66 Million EUR | 6.2% |
| 2019 FY | 511.21 Million EUR | 26.95% |
| 2019 Q3 | 452.17 Million EUR | 0.68% |
| 2018 Q1 | 307.31 Million EUR | 3.0% |
| 2018 Q3 | 316.15 Million EUR | 1.25% |
| 2018 Q2 | 312.24 Million EUR | 1.6% |
| 2018 FY | 402.7 Million EUR | 34.96% |
| 2018 Q4 | 402.7 Million EUR | 27.37% |
| 2017 Q4 | 298.38 Million EUR | 3.02% |
| 2017 FY | 298.38 Million EUR | 3.66% |
| 2017 Q3 | 289.62 Million EUR | -4.42% |
| 2017 Q2 | 303 Million EUR | 0.35% |
| 2017 Q1 | 301.94 Million EUR | 4.9% |
| 2016 FY | 287.84 Million EUR | 9.1% |
| 2016 Q3 | 271.32 Million EUR | -2.61% |
| 2016 Q2 | 278.59 Million EUR | 4.97% |
| 2016 Q1 | 265.4 Million EUR | 0.59% |
| 2016 Q4 | 287.84 Million EUR | 6.09% |
| 2015 Q1 | 261.88 Million EUR | 0.21% |
| 2015 FY | 263.84 Million EUR | 0.97% |
| 2015 Q4 | 263.84 Million EUR | 0.67% |
| 2015 Q3 | 262.08 Million EUR | -0.95% |
| 2015 Q2 | 264.59 Million EUR | 1.04% |
| 2014 Q2 | 247.64 Million EUR | 4.67% |
| 2014 Q1 | 236.59 Million EUR | 0.28% |
| 2014 FY | 261.32 Million EUR | 10.76% |
| 2014 Q4 | 261.32 Million EUR | 6.52% |
| 2014 Q3 | 245.32 Million EUR | -0.93% |
| 2013 Q3 | 236.08 Million EUR | 2.93% |
| 2013 FY | 235.92 Million EUR | 6.1% |
| 2013 Q4 | 235.92 Million EUR | -0.07% |
| 2013 Q1 | 224.99 Million EUR | 1.18% |
| 2013 Q2 | 229.37 Million EUR | 1.95% |
| 2012 Q4 | 222.36 Million EUR | 0.0% |
| 2012 FY | 222.36 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Boiron SA | 590.2 Million EUR | -35.527% |
| Vetoquinol SA | 692.23 Million EUR | -15.551% |
| Valneva SE | 469.39 Million EUR | -70.409% |
| AB Science S.A. | 25.49 Million EUR | -3036.923% |
| Nanobiotix S.A. | 93.89 Million EUR | -751.874% |
| PHAXIAM Therapeutics S.A. | 51.3 Million EUR | -1459.015% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -2494.583% |
| BioSenic S.A. | 9.55 Million EUR | -8267.863% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -144.566% |
| Formycon AG | 890.36 Million EUR | 10.162% |